128 related articles for article (PubMed ID: 23600137)
1. [Advances in the study of steroidal inhibitors of cytochrome P45017alpha].
Du JJ; Chen HL; Li YC
Yao Xue Xue Bao; 2013 Jan; 48(1):25-31. PubMed ID: 23600137
[TBL] [Abstract][Full Text] [Related]
2. Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors.
Cai C; Chen S; Ng P; Bubley GJ; Nelson PS; Mostaghel EA; Marck B; Matsumoto AM; Simon NI; Wang H; Chen S; Balk SP
Cancer Res; 2011 Oct; 71(20):6503-13. PubMed ID: 21868758
[TBL] [Abstract][Full Text] [Related]
3. The 16,17-double bond is needed for irreversible inhibition of human cytochrome p45017alpha by abiraterone (17-(3-pyridyl)androsta-5, 16-dien-3beta-ol) and related steroidal inhibitors.
Jarman M; Barrie SE; Llera JM
J Med Chem; 1998 Dec; 41(27):5375-81. PubMed ID: 9876107
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of p450 17 as a new strategy for the treatment of prostate cancer.
Leroux F
Curr Med Chem; 2005; 12(14):1623-9. PubMed ID: 16022662
[TBL] [Abstract][Full Text] [Related]
5. 17alpha-hydroxylase/17,20-lyase (p450(17alpha)) inhibitors in the treatment of prostate cancer: a review.
Owen CP
Anticancer Agents Med Chem; 2009 Jul; 9(6):613-26. PubMed ID: 19601745
[TBL] [Abstract][Full Text] [Related]
6. Synthesis, biological evaluation, and molecular modeling of abiraterone analogues: novel CYP17 inhibitors for the treatment of prostate cancer.
Pinto-Bazurco Mendieta MA; Negri M; Jagusch C; Müller-Vieira U; Lauterbach T; Hartmann RW
J Med Chem; 2008 Aug; 51(16):5009-18. PubMed ID: 18672868
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and evaluation of 17-aliphatic heterocycle-substituted steroidal inhibitors of 17alpha-hydroxylase/C17-20-lyase (P450 17).
Hartmann RW; Hector M; Wachall BG; Palusczak A; Palzer M; Huch V; Veith M
J Med Chem; 2000 Nov; 43(23):4437-45. PubMed ID: 11087568
[TBL] [Abstract][Full Text] [Related]
8. N-substituted piperazinopyridylsteroid derivatives as abiraterone analogues inhibit growth and induce pro-apoptosis in human hormone-independent prostate cancer cell lines.
Brossard D; Zhang Y; Haider SM; Sgobba M; Khalid M; Legay R; Duterque-Coquillaud M; Galera P; Rault S; Dallemagne P; Moslemi S; El Kihel L
Chem Biol Drug Des; 2013 Nov; 82(5):620-9. PubMed ID: 23906044
[TBL] [Abstract][Full Text] [Related]
9. CYP17A1: a biochemistry, chemistry, and clinical review.
Porubek D
Curr Top Med Chem; 2013; 13(12):1364-84. PubMed ID: 23688130
[TBL] [Abstract][Full Text] [Related]
10. Novel steroidal pyrimidyl inhibitors of P450 17 (17 alpha-hydroxylase/C17-20-lyase).
Haidar S; Ehmer PB; Hartmann RW
Arch Pharm (Weinheim); 2001 Dec; 334(12):373-4. PubMed ID: 11852531
[No Abstract] [Full Text] [Related]
11. Novel 17-azolyl steroids, potent inhibitors of human cytochrome 17 alpha-hydroxylase-C17,20-lyase (P450(17) alpha): potential agents for the treatment of prostate cancer.
Njar VC; Kato K; Nnane IP; Grigoryev DN; Long BJ; Brodie AM
J Med Chem; 1998 Mar; 41(6):902-12. PubMed ID: 9526564
[TBL] [Abstract][Full Text] [Related]
12. Stepwise binding of inhibitors to human cytochrome P450 17A1 and rapid kinetics of inhibition of androgen biosynthesis.
Guengerich FP; McCarty KD; Chapman JG; Tateishi Y
J Biol Chem; 2021 Aug; 297(2):100969. PubMed ID: 34273352
[TBL] [Abstract][Full Text] [Related]
13. [Inhibitors of the key enzymes of androgen synthesis: potential agents as targets for prostate cancer].
Takeda M; Hosaka M
Nihon Rinsho; 2000 Jul; 58 Suppl():312-6. PubMed ID: 11022738
[No Abstract] [Full Text] [Related]
14. Steroid synthesis inhibition by ketoconazole: sites of action.
Trachtenberg J; Zadra J
Clin Invest Med; 1988 Feb; 11(1):1-5. PubMed ID: 2966691
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and evaluation of novel steroidal oxime inhibitors of P450 17 (17 alpha-hydroxylase/C17-20-lyase) and 5 alpha-reductase types 1 and 2.
Hartmann RW; Hector M; Haidar S; Ehmer PB; Reichert W; Jose J
J Med Chem; 2000 Nov; 43(22):4266-77. PubMed ID: 11063622
[TBL] [Abstract][Full Text] [Related]
16. Inhibitors of steroidal cytochrome p450 enzymes as targets for drug development.
Baston E; Leroux FR
Recent Pat Anticancer Drug Discov; 2007 Jan; 2(1):31-58. PubMed ID: 18221052
[TBL] [Abstract][Full Text] [Related]
17. Environmental inhibitors of the expression of cytochrome P450 17A1 in mammals.
Peng Z; Xueb G; Chen W; Xia S
Environ Toxicol Pharmacol; 2019 Jul; 69():16-25. PubMed ID: 30921671
[TBL] [Abstract][Full Text] [Related]
18. Effects of novel 17alpha-hydroxylase/C17, 20-lyase (P450 17, CYP 17) inhibitors on androgen biosynthesis in vitro and in vivo.
Haidar S; Ehmer PB; Barassin S; Batzl-Hartmann C; Hartmann RW
J Steroid Biochem Mol Biol; 2003 Apr; 84(5):555-62. PubMed ID: 12767280
[TBL] [Abstract][Full Text] [Related]
19. Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001.
DeVore NM; Scott EE
Nature; 2012 Jan; 482(7383):116-9. PubMed ID: 22266943
[TBL] [Abstract][Full Text] [Related]
20. Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer.
Hofland J; van Weerden WM; Dits NF; Steenbergen J; van Leenders GJ; Jenster G; Schröder FH; de Jong FH
Cancer Res; 2010 Feb; 70(3):1256-64. PubMed ID: 20086173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
